LAURA RICCARDI: Open Payments
NPI 1700581659 · CARNEYS POINT, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,499 in 92 payments from 14 companies in 2025. Trend: 2023 $446 · 2024 $1,589 · 2025 $1,499
Food & beverage: $1,499
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 14 | $263 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $237 |
| Otsuka America Pharmaceutical, Inc. | 13 | $202 |
| ABBVIE INC. | 21 | $182 |
| Teva Pharmaceuticals USA, Inc. | 13 | $160 |
| Janssen Pharmaceuticals, Inc | 5 | $124 |
| E.R. Squibb & Sons, L.L.C. | 5 | $91 |
| Vanda Pharmaceuticals Inc. | 4 | $75 |
| Axsome Therapeutics, Inc. | 4 | $72 |
| Almatica Pharma LLC | 2 | $31 |
Products named: INGREZZA, CAPLYTA, VRAYLAR, REXULTI, COBENFY, AUSTEDO XR, INVEGA, UZEDY.
Industry payments across NJ — which companies pay providers there.
